In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
|Articles|October 1, 2006
Applied Clinical Trials Supplements
- Supplements-11-15-2007
- Volume 0
- Issue 0
eShowcase: LabPas CT 2.5
Phase I package adds formulary accountability, recruitment, lab, and EDC features
Advertisement
Phase I package adds formulary accountability, recruitment, lab, and EDC features
LabPas CT 2.5
Green Mountain Logic (Montpellier, VT) has added formulary accountability, recruitment, clinical lab, and EDC components to LabPas CT, its software package designed for Phase I management. LabPas CT 2.5 deploys PDAs on clinic floors for scanning patient and collection vessel barcodes and RFIDs to eliminate error potential. It provides real-time electronic data entry for collection times, comments, dosing, vital signs, and adverse events, and can adapt to changing protocols.
Enhancements in the latest version of LabPas CT allow users to track and manage the entire fomulary chain including accountability, distribution, reconciliation, returns, and destruction. The package also allows users to manage subject information such as biometrics, and handles scheduling and study assignment tasks. Also, the new clinical lab component of LabPas CT integrates clinical trial results into the study database, and the software exports clinical study data in a variety of formats for easy eCRF creation.
Green Mountain Logic, (866) LABPAS1,
Articles in this issue
about 19 years ago
eShowcase: Laboratory and Clinical Study Statusabout 20 years ago
The Central Laboratory: 20 Years of Evolutionabout 20 years ago
Clinical Lab DirectoryAdvertisement
Related to this article
The new effort combines adaptive platform trial design, AI-enabled site activation, nationwide data infrastructure, and patient data contribution tools to reduce timelines, costs, and patient burden across clinical development.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is shifting trial risk management from reactive to proactive—enabling sponsors to pressure-test protocols and anticipate pivots before a single patient is enrolled.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
AI agents in clinical operations acquire broader autonomous capability through expanded permissions, tools, memory, and delegated authority, requiring governance focused on whether effective capability has shifted outside approved boundaries rather than whether software has changed.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
RWE is finding a role earlier in drug development than ever before, but the data quality, integration, and organizational alignment required to make it regulatory-grade are still catching up to the ambition.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
2
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
3
Where AI Leads in Trial Design—and Where Humans Still Need To
4
What an AI-Informed Approach Means for How Sponsors Think About Risk
5